Regal Partners Ltd Makes New Investment in Hims & Hers Health, Inc. (NYSE:HIMS)

Key Points

• Regal Partners Ltd acquired 29,936 shares of Hims & Hers Health, valued at approximately $885,000, highlighting increasing institutional interest in the company.
• Insider Patrick Harrison Carroll sold 60,000 shares of Hims & Hers Health, indicating a 26.09% decrease in his position, as total insider sales over the last ninety days reached approximately $77.4 million.
• Hims & Hers Health reported $0.17 earnings per share for the latest quarter, missing estimates and showing a 72.6% increase in revenue year-over-year.

Regal Partners Ltd purchased a new position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 29,936 shares of the company's stock, valued at approximately $885,000.

Other large investors also recently bought and sold shares of the company. Signaturefd LLC increased its holdings in shares of Hims & Hers Health by 17.7% in the first quarter. Signaturefd LLC now owns 2,586 shares of the company's stock valued at $76,000 after purchasing an additional 388 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Hims & Hers Health during the fourth quarter worth $18,048,000. GAMMA Investing LLC boosted its position in shares of Hims & Hers Health by 128.5% during the first quarter. GAMMA Investing LLC now owns 5,143 shares of the company's stock worth $152,000 after buying an additional 2,892 shares during the period. New York State Teachers Retirement System boosted its position in shares of Hims & Hers Health by 95.2% during the first quarter. New York State Teachers Retirement System now owns 194,795 shares of the company's stock worth $5,756,000 after buying an additional 94,983 shares during the period. Finally, BNP Paribas Financial Markets purchased a new position in shares of Hims & Hers Health during the fourth quarter worth $1,230,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Hims & Hers Health Price Performance

HIMS stock traded up $0.38 on Wednesday, reaching $48.34. The company had a trading volume of 19,190,097 shares, compared to its average volume of 37,543,556. Hims & Hers Health, Inc. has a 1 year low of $13.47 and a 1 year high of $72.98. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. The company's fifty day moving average is $53.28 and its 200 day moving average is $45.32. The company has a market cap of $10.82 billion, a P/E ratio of 60.43, a PEG ratio of 3.04 and a beta of 2.08.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The company had revenue of $544.83 million during the quarter, compared to analysts' expectations of $550.06 million. During the same period in the previous year, the company posted $0.06 EPS. Hims & Hers Health's quarterly revenue was up 72.6% compared to the same quarter last year. On average, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on HIMS. UBS Group set a $30.00 price target on Hims & Hers Health in a research report on Monday, June 23rd. TD Cowen lowered Hims & Hers Health from a "buy" rating to a "hold" rating and decreased their target price for the company from $44.00 to $30.00 in a report on Tuesday, April 29th. Truist Financial lifted their target price on Hims & Hers Health from $45.00 to $48.00 and gave the company a "hold" rating in a report on Thursday, July 17th. Wall Street Zen lowered Hims & Hers Health from a "buy" rating to a "hold" rating in a report on Monday, July 28th. Finally, Morgan Stanley reiterated an "equal weight" rating and issued a $40.00 target price on shares of Hims & Hers Health in a report on Wednesday, June 11th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, Hims & Hers Health presently has an average rating of "Hold" and a consensus price target of $39.83.

Insider Buying and Selling

In other Hims & Hers Health news, CEO Andrew Dudum sold 660,000 shares of the business's stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $50.58, for a total value of $33,382,800.00. Following the completion of the transaction, the chief executive officer directly owned 2,214,769 shares in the company, valued at approximately $112,023,016.02. The trade was a 22.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Soleil Boughton sold 2,572 shares of the company's stock in a transaction on Monday, August 11th. The stock was sold at an average price of $51.64, for a total value of $132,818.08. Following the sale, the insider owned 153,021 shares of the company's stock, valued at approximately $7,902,004.44. The trade was a 1.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,460,276 shares of company stock worth $77,374,454 in the last quarter. Corporate insiders own 13.71% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.